HRS/ACC/AHA Expert Consensus Statement on the Use of ICD Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials

Published: May 09, 2014

Science News on light gray background
  • The use of implantable cardioverter-defibrillator (ICD) therapy is a widely accepted and important treatment for patients with cardiovascular disease who are at risk for life-threatening ventricular arrhythmias.
  • Situations still exist that aren’t addressed by existing guidelines, which are limited to those specific populations in the trials included in those guidelines.
  • This joint consensus statement helps identify those patients who will receive optimal benefit from the timely use of ICD therapy.